Table 1 Characteristics of the low dose combination drug regimen applied in this study compared to commonly used doses.

From: Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts

Target

Drug

Selected low dose combination therapy

Common dosing in vivo models

Dosing

Schedule

Dosing

Schedule

VEGFR2 (KDR)/MET

Cabozantinib

15 mg/kg

5 days on/2 days off for 4 cycles

30–60 mg/kg26,49

once daily

CXCR4

Plerixafor

5 mg/kg

5 mg/kg28

EGFRwt

Afatinib

15 mg/kg

20 mg/kg

COX2 (PTGS2)

Etoricoxib

10 mg/kg

10 mg/kg29

Back to article page